Company Overview
Ascendis Pharma is a biopharmaceutical company headquartered in Denmark that develops prodrug therapies built on its TransCon technology platform. The platform is designed to release a parent drug at a predictable rate, supporting less frequent dosing, and the company applies it across endocrinology, rare disease and oncology programmes.
Recent Leadership News
Amer Mirza, formerly Vice President of Biomarker Discovery and Development at Ascendis Pharma, was appointed Chief Scientific Officer at Prolynx in July 2026.
Facts compiled by Executive Moves from publicly available news and press releases on 17 July 2026. Spotted an inaccuracy? Email us and we'll review within 1 business day.
To upgrade to a Premium Profile reach out to us at info@executive-moves.com.
Are you on the Ascendis Pharma team?
This is a Light company page, auto-generated from public news coverage. Claim it to verify the company description, add logo and links, and control how your organisation is represented on Executive Moves.
Claim this company →
